Paromomycin
- PMID: 18947845
- DOI: 10.1016/j.trstmh.2008.09.008
Paromomycin
Abstract
Paromomycin is an aminoglycoside that is active against Gram-negative and many Gram-positive bacteria as well as some protozoa and cestodes. It is out of use as an antibiotic but was licensed in 2007 in India as an effective, well tolerated and affordable treatment for visceral leishmaniasis (VL) at a dose of 11 mg/kg (base) for 21 days. Currently, the non-profit group Drugs for Neglected Diseases Initiative is conducting studies on paromomycin (as monotherapy and in combination) in VL in Africa, and the Institute for OneWorld Health is conducting a Phase IV study in India. Paromomycin in combination with sodium stibogluconate has proven to be effective in African and Indian VL and improves survival in African VL. To prevent the emergence of drug-resistant leishmaniasis in areas of anthroponotic transmission (India and Africa), paromomycin should be used as part of combination therapy for VL. Further trials testing different combinations are much needed. In addition, the distribution of paromomycin (like other drugs for leishmaniasis) should be well regulated and preferably restricted to the public sector. These strategies should ensure the longevity of paromomycin as a useful drug for VL.
Similar articles
-
Drug combinations for visceral leishmaniasis.Curr Opin Infect Dis. 2010 Dec;23(6):595-602. doi: 10.1097/QCO.0b013e32833fca9d. Curr Opin Infect Dis. 2010. PMID: 20871400 Review.
-
Short-course paromomycin treatment of visceral leishmaniasis in India: 14-day vs 21-day treatment.Clin Infect Dis. 2009 Sep 15;49(6):914-8. doi: 10.1086/605438. Clin Infect Dis. 2009. PMID: 19663597 Clinical Trial.
-
Injectable paromomycin for Visceral leishmaniasis in India.N Engl J Med. 2007 Jun 21;356(25):2571-81. doi: 10.1056/NEJMoa066536. N Engl J Med. 2007. PMID: 17582067 Clinical Trial.
-
Sodium stibogluconate-sensitive visceral leishmaniasis in the non-endemic hilly region of Uttarakhand, India.Trans R Soc Trop Med Hyg. 2007 Jul;101(7):730-2. doi: 10.1016/j.trstmh.2007.02.008. Epub 2007 Mar 23. Trans R Soc Trop Med Hyg. 2007. PMID: 17382981
-
Management of visceral leishmaniasis: Indian perspective.J Postgrad Med. 2005;51 Suppl 1:S53-7. J Postgrad Med. 2005. PMID: 16519257 Review.
Cited by
-
Treatment of Dientamoeba fragilis: A retrospective Finnish analysis of faecal clearance and clinical cure comparing four antiprotozoal drugs.New Microbes New Infect. 2023 Sep 23;54:101179. doi: 10.1016/j.nmni.2023.101179. eCollection 2023 Sep. New Microbes New Infect. 2023. PMID: 37786407 Free PMC article.
-
Restoring susceptibility to aminoglycosides: identifying small molecule inhibitors of enzymatic inactivation.RSC Med Chem. 2023 Jul 21;14(9):1591-1602. doi: 10.1039/d3md00226h. eCollection 2023 Sep 19. RSC Med Chem. 2023. PMID: 37731693 Review.
-
Drug-Repurposing Approach To Combat Staphylococcus aureus: Biomolecular and Binding Interaction Study.ACS Omega. 2022 Oct 18;7(43):38448-38458. doi: 10.1021/acsomega.2c03671. eCollection 2022 Nov 1. ACS Omega. 2022. PMID: 36340146 Free PMC article.
-
Carbohydrate-based drugs launched during 2000-2021.Acta Pharm Sin B. 2022 Oct;12(10):3783-3821. doi: 10.1016/j.apsb.2022.05.020. Epub 2022 May 23. Acta Pharm Sin B. 2022. PMID: 36213536 Free PMC article. Review.
-
The increasing incidence of visceral leishmaniasis relapse in South Sudan: A retrospective analysis of field patient data from 2001-2018.PLoS Negl Trop Dis. 2022 Aug 18;16(8):e0010696. doi: 10.1371/journal.pntd.0010696. eCollection 2022 Aug. PLoS Negl Trop Dis. 2022. PMID: 35981057 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources